June 3, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com
10 S. Riverside Plaza, Chicago, IL 60606

Evaxion Biotech (EVAX-NASDAQ)

EVAX: Grant For Polio Vaccine Announced

EVAX is using well-developed AI technology in the pursuit of important treatments. We value EVAX at $19.75 using discounted cash flow analysis with a 10% discount rate.

Current Price (06/02/25)	$2.72
Valuation	**$19.75**

OUTLOOK

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments. The company has two streams of possible revenue: from the treatments themselves and from the licensing of AI technology.

The company announced it received a grant to develop a new and unique vaccine with the goal of eradicating polio. This provides further proof of the scientific community's belief in the EVAX approach.

SUMMARY DATA

52-Week High	**$18.35**
52-Week Low	**$1.30**
One-Year Return (%)	**-84.54**
Beta	**0.10**
Average Daily Volume (sh)	**130,118**
Shares Outstanding (mil)	**6.3**
Market Capitalization ($mil)	**$17.1**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**11**
Insider Ownership (%)	**42**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2024 Estimate	**N/A**
P/E using 2025 Estimate	**N/A**

Risk Level	**Above Avg.**
Type of Stock	**Biotech**

ZACKS ESTIMATES

Revenue
(in thousands of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	73 A
2024	51 A	154 A	3017 A	122 A	3344 A
2025	0 A	0 E	0 E	0 E	0 E
2026	0 E	0 E	0 E	0 E	0 E

Earnings per ADS Share (USD)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2023	NA	NA	NA	NA	-0.81 A
2024	0.03 A	-0.12 A	-0.04 A	-0.07 A	-0.20 A
2025	-0.50 A	-0.50 E	-0.50 E	-0.50 E	-2.00 E*
2026	-0.50 E	-0.50 E	0.00 E	-0.00 E	-1.00 E

* ADS ratio was changed in Q1 2025.

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

Update

Evaxion (EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has demonstrated that it can identify, through the company's AI models, novel targets within days, rather than the traditional years it commonly takes with standard drug discovery methods. The use of AI also allows the company to decrease the risk of failure as the technology filters out those results that may result in low efficacy or unacceptable toxicity.

Adding to the company's string of positive developments recently, the company announced that it has been awarded a grant from the Gates Foundation to explore design options for new and unique vaccine for polio. Polio cases have been reduced greatly but remains endemic in two countries according to the World Health Organization. These remaining countries could be the source of a global resurgence in the disease, which is why the WHO places a high priority on eradicating the disease. Polio isn't mentioned much in the United States anymore but is a very serious disease the mainly affects children, with 1 in 200 of those that get infected getting irreversible paralysis that could lead to death.

Existing vaccines have been very effective but are based on an inactive version of the virus, which could create "significant issues in certain settings" according to the company. The EVAX approach is to use its AI-Immunology platform to identify and combine various antigens to fight polio in a new way, using a vaccine that doesn't contain a live version of the virus.

We believe this is an important announcement for two reasons. First, eradicating polio would be very beneficial to the world population and second, it illustrates further the value and belief of the scientific community in the EVAX approach.

Additionally, the company also recently announced data for its lead cancer vaccine EVX-01 that is being developed as a treatment for advanced melanoma. The new Phase 2 trial data showed that 80% of EVX-01 vaccine targets trigged a tumor-specific immune response. This is an improvement from the still impressive 71% and 79% hit rates announced previously.

The trend of the data getting better as time goes on is extremely encouraging for the treatments prospects and we are looking forward to the full two-year readout of clinical data in the second half of 2025. This builds on the encouraging news that the company is extending its trial of EVX-01 to a third year so that the company can better explore the full potential of the treatment.

Company management also recently noted that the company expects to use its proprietary AI-Immunology to identify two new vaccine candidates for infectious diseases in 2025—further broadening the company's pipeline and providing more opportunities for patient treatment.

We continue to be excited about the investment opportunities offered by EVAX. In our view, these announcements are the tip of the iceberg of what the AI platforms developed by Evaxion can achieve and positive news will continue to come out as we move forward. We suggest investors investigate EVAX further and consider investing, as we believe the company is at an inflection point that is the start of sustained uptrend.

PROJECTED INCOME STATEMENT & BALANCE SHEET

Evaxion Pharmaceuticals Income Statement and Balance Sheet									
	1Q2024A	2Q2024A	3Q2024A	4Q2024A	1Q2025A	2Q2025E	3Q25025E	4Q2025E	2026E
Revenue	51	154	3,017	122	0	0	0	0	0
Operating Costs:									
Research and Development	(2,836)	(2,752)	(2,614)	(2,255)	(2,156)	(2,199)	(2,243)	(2,288)	(9,152)
General and Admistrative	(1,611)	(1,983)	(2,134)	(1,891)	(1,712)	(1,746)	(1,781)	(1,817)	(7,267)
Total Operating Gain/(Loss)	(4,396)	(4,581)	(1,731)	(4,024)	(3,868)	(3,945)	(4,024)	(4,105)	(16,419)
Finance Income	5,618	220	84	578	2,493	2,518	2,543	2,569	10,274
Finance Expenses	(246)	(2,036)	(384)	(458)	(397)	(401)	(405)	(409)	(1,636)
Other Income/(Expenses)	-	-	-	-	-				-
Income Tax Benefit	218	199	96	275	192	0	0	0	0
Net Gain/(Loss)	1,194	(6,198)	(1,935)	(3,629)	(1,580)	(1,828)	(1,886)	(1,945)	(7,781)
Basic and diluted loss per share	0.03	(0.12)	(0.04)	(0.07)	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)
Common Shares Outstanding	48,638,239	53,787,469	55,255,329	53,644,483	276,311,927	290,127,523	304,633,900	319,865,594	335,858,874
Assets									
Current Assets									
Cash and cash equivalents	11,731	7,993	4,576	5,952	17,843	16,059	14,453	13,008	11,707
Other Assets	10,923	7,238	10,609	6,533	7,396	6,656	5,991	5,392	4,853
Total Assets	22,654	15,231	15,185	12,485	25,239	22,715	20,444	18,399	16,559
Liabilities and SH deficit (equity)									
Total Liabilities	20,050	13,978	15,111	14,137	14,896	15,194	15,498	15,808	16,124
Share Capital	7,964	8,244	8,732	10,516	11,823	11,941	12,061	12,181	12,303
Other Reserves	109,602	105,983	106,245	106,369	118,632	119,818	121,017	122,227	123,449
Accumulated Deficit	(112,033)	(112,974)	(114,903)	(118,537)	(120,112)	(124,238)	(128,131)	(131,817)	(135,317)
Effect from der. Liab. From warrants	(2,929)	0	0	0	0	0	0	0	0
Total SH deficit/(equity)	2,604	1,253	74	(1,652)	10,343	7,521	4,947	2,591	435
Total Liabilities and SH deficit/(equity)	22,654	15,231	15,185	12,485	25,239	22,715	20,444	18,399	16,559

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.